Procter & Gamble completes game-changing acquisition of Merck’s consumer health unit

Procter & Gamble completes game-changing acquisition of Merck’s consumer health unit

In a significant boost to its consumer health portfolio, Procter & Gamble (P&G) has concluded its €3.4 billion acquisition of German pharmaceutical giant Merck’s consumer health business. This move, first announced in April 2018, aims to elevate P&G’s position in the global over-the-counter (OTC) health market, adding extensive geographical scale and expanding its presence across […]

Procter & Gamble to acquire Merck’s consumer health business for €3.4bn

Procter & Gamble to acquire Merck’s consumer health business for €3.4bn

Procter & Gamble (P&G), a leading US consumer goods company, has finalized a deal to acquire the consumer health business of German pharmaceutical company Merck for approximately €3.4 billion ($4.2 billion). This all-cash transaction marks a significant expansion of P&G’s consumer health division by incorporating a range of over-the-counter (OTC) products from Merck. Expanding P&G’s […]

GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn

GlaxoSmithKline to acquire full ownership of consumer healthcare venture from Novartis for $13bn

In a major strategic shift, GlaxoSmithKline (GSK) has finalized an agreement to acquire Novartis’ 36.5% stake in their consumer healthcare joint venture for $13 billion. This move comes shortly after GSK withdrew from a $20 billion bid to purchase Pfizer’s consumer healthcare business, indicating a focused realignment of GSK’s investment towards owning 100% of its […]

Pfizer faces setback as Reckitt Benckiser and GSK withdraw from $20bn consumer health deal

Pfizer faces setback as Reckitt Benckiser and GSK withdraw from $20bn consumer health deal

Pfizer’s $20 Billion Sale Stalls: In a significant turn of events in the pharmaceutical industry, both Reckitt Benckiser and GlaxoSmithKline (GSK) have decided to withdraw from acquisition talks with Pfizer regarding its consumer healthcare business. This decision marks a setback for Pfizer’s plans to offload this segment, valued at approximately $20 billion. Overview of Pfizer’s […]